middle.news
ReNerve Surges with 260% Sales Growth and Expands Into Asia and Middle East
9:57am on Wednesday 29th of January, 2025 AEDT
•
Biotechnology
Read Story
ReNerve Surges with 260% Sales Growth and Expands Into Asia and Middle East
9:57am on Wednesday 29th of January, 2025 AEDT
Key Points
260% sales growth in Q2 FY25 compared to prior year
Raised A$7 million in heavily oversubscribed IPO at $0.20 per share
Exclusive distribution agreements secured in Hong Kong, Macau, and Middle East
Clinical study results for NervAlign® Nerve Cuff expected late Q3 FY25
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Renerve (ASX:RNV)
OPEN ARTICLE